Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to $59.1 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.37% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 1.37%. This contributed to the annual value of $58.3 million for FY2024, which is 1.35% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) is $59.1 million, which was up 0.26% from $58.9 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $59.1 million during Q3 2025, and its lowest value of $54.9 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $58.2 million (2024), whereas its average is $58.1 million.
  • Data for Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 2.75% (in 2023) over the last 5 years.
  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $55.7 million in 2021, then rose by 1.93% to $56.8 million in 2022, then grew by 1.32% to $57.5 million in 2023, then climbed by 1.35% to $58.3 million in 2024, then increased by 1.37% to $59.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $59.1 million in Q3 2025, compared to $58.9 million in Q2 2025 and $58.3 million in Q1 2025.